Verve Therapeutics, Inc.
Acquired
Matched to this startup by its exact name; the buyer's report is the source.
| Acquired | Buyer | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|---|
| Verve Therapeutics, Inc | Eli Lilly and Company | 2025 | — | $549 M | — | Annual report |
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2021 | $94 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Verve Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).
SEC Form D · Jan 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2021
That is all the official record says: Verve Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
26 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | Venture capital | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Fund X Overage, L.P. | Venture capital | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X, LLC | Venture capital | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X, L.P. | Venture capital | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X Overage, L.P. | Venture capital | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Beam Therapeutics Inc. | Company | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Biomatics Capital Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Casdin Partners Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Casdin Private Growth Equity Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund III LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A and A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2017 GP, L.L.C. | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2017 GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2017, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2019 GP, L.L.C. | Other | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2019 GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2019, L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Logos Global Management LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Rock Springs Capital LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Rock Springs Capital Management LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Rock Springs Capital Master Fund LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 22 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew Ashe | Executive officer | Jan 2021 |
| Andrew Bellinger | Executive officer | Jan 2021 |
| Sekar Kathiresan | Executive officer | Jan 2021 |
| Anthony Philippakis | Director | Jan 2021 |
| Burt Adelman | Director | Jan 2021 |
| John Evans | Director | Jan 2021 |
| Krishna Yeshwant | Director | Jan 2021 |
| Sekar Kathiresan | Director | Jan 2021 |
Acquired (Jan 1, 2025). Acquired by Eli Lilly and Company.